Skip to main content
Caplight Logo









Dermaliq Therapeutics, Inc.

Dermaliq Therapeutics, Inc.

Private
Wilmington, DelawareHealthcare & Life Scienceshttps://dermaliq.com

Last Round

Strategic

May 28, 2025

Total Funding Raised

$15M

Company Overview

Dermaliq Therapeutics, Inc. is a clinical-stage dermatology company developing topical therapies for follicular diseases and conditions using its proprietary hyliQ® technology platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B2C

Customer Profile

Revenue Share, Hardware Sales

AI Layer

Non-AI

Keywords

topical drug deliveryhyliQ platformdrug delivery platformdermatology therapeuticsalopecia treatmenthair loss treatmentpsoriasis treatmentEpidermolysis Bullosabutterfly skin diseasedrug formulationtargeted drug deliveryhair follicle deliveryclinical-stage pharmarare disease treatmentmedical aestheticslipophilic excipientsover-the-counter drugsOTC

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Dermaliq Therapeutics, Inc. Comparables

Compare Dermaliq Therapeutics, Inc. with similar companies based on industry and business-model similarity.

Dermaliq Therapeutics, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Alys Pharmaceuticals
79%
Atticus Pharma
79%
Follicle Pharma
77%

Dermaliq Therapeutics, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
StrategicMay 28, 2025
Series BFeb 5, 2025
Series AJan 18, 2022

Dermaliq Therapeutics, Inc. Investors

Notable investors and investment history

Dermaliq Therapeutics, Inc. investors
InvestorRounds
DEBRA Research gGmbHStrategic

Dermaliq Therapeutics, Inc. Filings

Explore SEC and related filing metadata, where available.

Dermaliq Therapeutics, Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Dermaliq Therapeutics, Inc.'s valuation, stock price, and market status.

Is Dermaliq Therapeutics, Inc. a public or private company?

Dermaliq Therapeutics, Inc. is a private company.

What is the current stock price of Dermaliq Therapeutics, Inc.?

Dermaliq Therapeutics, Inc. is a private company with no public stock price. No recent secondary market data is available.

How much is Dermaliq Therapeutics, Inc. worth (valuation)?

Valuation information for Dermaliq Therapeutics, Inc. is not publicly available.

Can I buy Dermaliq Therapeutics, Inc. stock?

Dermaliq Therapeutics, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Dermaliq Therapeutics, Inc.'s last funding round?

Dermaliq Therapeutics, Inc.'s most recent funding round was Strategic on May 28, 2025.

Who are the main investors in Dermaliq Therapeutics, Inc.?

Key investors in Dermaliq Therapeutics, Inc. include DEBRA Research gGmbH.

Will Dermaliq Therapeutics, Inc. IPO soon?

No public IPO plans have been announced for Dermaliq Therapeutics, Inc..

How can I track Dermaliq Therapeutics, Inc. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Dermaliq Therapeutics, Inc.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersWilmington, Delaware
Employee Range6
Year Founded2021
Last FundingMay 28, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?